Great review article on immune checkpoint blockade in #hematologic malignancies by Philippe Armand in latest issue (May 28) of #Blood

#ASCO Oral Session for #Leukemia/#BMT on Sat 5/30 1:15-4:15 PM Arie Crown Theater E

#ASCO Poster Discussion on #Leukemia/#BMT on Sun 5/31 11:30-12:45 PM Convention Center E354b

#ASCO #BMT\#Leukemia oral presentations in Arie Crown Theatre at 1:15PM

#ASCO15 3 distinct LSC phenotypes in #AML correlate with outcomes. Only LT survivors with high ALDH phenotype was with allogeneic #BMT

#ASCO15 #CLL-IPI introduced.

#ASCO15 #CLL-IPI

#ASCO15 Wendy Stock comment on CLL-IPI

#ASCO15 #Leukemia FLT3 inhibitor ASP2215 phase 1/2 trial: no DLT, MTD 450mg 47% CR rate, med response duration 4 months

#ASCO15 #CLL phase3 HELIOS trial: ibrutinb(I)+BR vs placebo+BR. I+BR results in superior ORR/CR and PFS HR=0.2 in relapsed #CLL

#ASCO15 #CLL HELIOS trial: ibrutinb(I)+BR vs placebo+BR in relapsed No difference in OS but placebo progressors allowed to cross over to I

#ASCO15 PERSIST-1 trial in #myelofibrosis demonstrates superior spleen size reduction with pacritinib against best available therapy

#ASCO15 discussant Lloyd Damon assessment that #HELIOS trial an advance in CLL but did it ask best question (ie needed #ibrutinb alone arm)?

#asco15 PFS directly associated with adherence to ibrutinib in #CLL treatment

#ASCO2015 report of low % of patients being tested IVGH in #CLL workup. Relevant as IVGH status is part of new #CLL-IPI presented yesterday

#ASCO2015 #AML prelim results from intergroup trial S0535 for #APL show low induction mortality (11%); outcome data still pending (#ASH?)

#ASCO2015 Bone marrow blast % correlates with OS across various treatments in high-risk #MDS. Possible new prognostic and response marker

Ford et al report on largest series (n= 125) of #BMT for Jehovah Witnesses in J Clin Oncol 33:1674,2015. 17 bleeding episodes a/w plts <5K

outstanding precision medicine piece: sciencemag.org/content/349/62…

Taking part in Govt Affairs Committee ASH. Up to Hill tomorrow to ask for support for #SickleCell programs and funding!